Zogenix to Present at Two Investor Conferences in April

EMERYVILLE, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that members of management will participate on panels and host investor meetings at two conferences in April: Stifel First Annual CNS Day and William Blair 3rd Annual Late-Stage Therapeutics Conference.

About ZogenixZogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company’s lead candidate, FINTEPLA® (ZX008, fenfluramine) has been accepted for review by the European Medicines Agency; is awaiting an acceptance decision by the U.S. Food & Drug Administration; and is in development in Japan. For more information, visit www.zogenix.com.

CONTACT:ZogenixMelinda BakerSenior Director, Corporate Communications[email protected]

MediaRachel LipsitzPublic Relations, Syneos Health +1 (858) 449 9575 | [email protected]

Investors Andrew McDonaldFounding Partner, LifeSci Advisors LLC+1 (646) 597-6987 | [email protected]

You May Also Be Interested In

• Rescheduling Marijuana: The Bet That May Be About To Go Very Wrong
• Eve Air Mobility and Moov Sign LOI for up to 30 eVTOLs to Explore Tourism and Regional Mobility in Cabo Verde
• ChessDigital Launches the ChessDigital Listing Engine, an AI-Powered and Human-Supported Growth System for Real Estate Teams and Brokerages